Results 101 to 110 of about 395,425 (304)
Angiotensin II Type 1 Receptor Blockers [PDF]
Value in Health, 2018 L Luan, H Hu, SC Li
openaire +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients
British Journal of Clinical Pharmacology, EarlyView.Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel +12 more
wiley +1 more source
Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury
British Journal of Clinical Pharmacology, EarlyView.Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra +8 more
wiley +1 more source
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatology, EarlyView., 2022 Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park +22 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi +6 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pregabalin and duloxetine are widely prescribed non‐opioid medications for chronic musculoskeletal pain. Pregabalin may increase the risk of heart failure, and duloxetine increases heart rate and blood pressure; however, little is known about their comparative cardiovascular safety.
Sachalee Campbell +11 more
wiley +1 more source
陆军军医大学学报Objective To investigate the mechanism by which angiotensin Ⅱ type 1 receptor autoantibody (AT1-AA) promotes phenotypic switch of vascular smooth muscle cells (VSMCs) and vascular fibrosis through abnormal expression of circadian clock protein BMAL1.
XUE Lingxia, LONG Yaolin, FENG Jiayan
doaj +1 more source